NEUROCRINE BIOSCIENCES INC Operating Cash Flow
NEUROCRINE BIOSCIENCES INC (NBIX) reported Operating Cash Flow of $282.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $136.40M, a 33.73% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $145.80M, a 125.00% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $388.40M, a 60.16% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $227.50M, a 43.99% increase year-over-year.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for fiscal 2025 was $782.70M, a 31.46% increase from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for fiscal 2024 was $595.40M, a 52.71% increase from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for fiscal 2023 was $389.90M, a 14.88% increase from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC net cash provided by (used in) operating activities for fiscal 2022 was $339.40M, a 32.32% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $136.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $282.20M 10-Q · filed 2026-07-31 | $670.60M derived: sum of 3 quarters · filed 2026-07-31 | $898.10M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $145.80M 10-Q · filed 2026-05-05 | $534.20M derived: sum of 2 quarters · filed 2026-05-05 | $761.70M derived: sum of 3 quarters · filed 2026-05-05 | $863.70M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-12-31 | $388.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $615.90M derived: sum of 2 quarters · filed 2026-02-11 | $717.90M derived: sum of 3 quarters · filed 2026-07-31 | $782.70M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $227.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $329.50M derived: sum of 2 quarters · filed 2026-07-31 | $394.30M 10-Q · filed 2025-10-28 | $636.80M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-06-30 | $102.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | $166.80M 10-Q · filed 2026-07-31 | $409.30M derived: sum of 3 quarters · filed 2026-07-31 | $567.30M derived: sum of 4 quarters · filed 2026-07-31 | ||||
| 2025-03-31 | $64.80M 10-Q · filed 2026-05-05 | $307.30M derived: sum of 2 quarters · filed 2026-05-05 | $465.30M derived: sum of 3 quarters · filed 2026-05-05 | $529.90M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $242.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $400.50M derived: sum of 2 quarters · filed 2026-02-11 | $465.10M derived: sum of 3 quarters · filed 2026-02-11 | $595.40M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $158.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $222.60M derived: sum of 2 quarters · filed 2025-10-28 | $352.90M 10-Q · filed 2025-10-28 | $476.40M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $64.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $194.90M 10-Q · filed 2025-07-30 | $318.40M derived: sum of 3 quarters · filed 2026-02-11 | $530.40M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $130.30M 10-Q · filed 2025-05-05 | $253.80M derived: sum of 2 quarters · filed 2026-02-11 | $465.80M derived: sum of 3 quarters · filed 2026-02-11 | $645.40M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $123.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $335.50M derived: sum of 2 quarters · filed 2026-02-11 | $515.10M derived: sum of 3 quarters · filed 2026-02-11 | $389.90M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $212.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $391.60M derived: sum of 2 quarters · filed 2024-10-30 | $266.40M 10-Q · filed 2024-10-30 | $409.40M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | $179.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $54.40M 10-Q · filed 2024-08-01 | $197.40M derived: sum of 3 quarters · filed 2025-02-10 | $296.20M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | -$125.20M 10-Q · filed 2024-05-01 | $17.80M derived: sum of 2 quarters · filed 2025-02-10 | $116.60M derived: sum of 3 quarters · filed 2025-02-10 | $254.70M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | $143.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $241.80M derived: sum of 2 quarters · filed 2025-02-10 | $379.90M derived: sum of 3 quarters · filed 2025-02-10 | $339.40M 10-K · filed 2025-02-10 | ||||
| 2022-09-30 | $98.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $236.90M derived: sum of 2 quarters · filed 2023-10-31 | $196.40M 10-Q · filed 2023-10-31 | $200.60M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-06-30 | $138.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $97.60M 10-Q · filed 2023-08-01 | $101.80M derived: sum of 3 quarters · filed 2024-02-09 | $163.60M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2022-03-31 | -$40.50M 10-Q · filed 2023-05-03 | -$36.30M derived: sum of 2 quarters · filed 2024-02-09 | $25.50M derived: sum of 3 quarters · filed 2024-02-09 | $128.70M derived: sum of 4 quarters · filed 2024-02-09 | ||||
| 2021-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09 | $66.00M derived: sum of 2 quarters · filed 2024-02-09 | $169.20M derived: sum of 3 quarters · filed 2024-02-09 | $256.50M 10-K · filed 2024-02-09 | ||||
| 2021-09-30 | $61.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $165.00M derived: sum of 2 quarters · filed 2022-11-01 | $252.30M 10-Q · filed 2022-11-01 | $346.80M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $103.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $190.50M 10-Q · filed 2022-08-04 | $285.00M derived: sum of 3 quarters · filed 2023-02-09 | $264.60M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $87.30M 10-Q · filed 2022-05-04 | $181.80M derived: sum of 2 quarters · filed 2023-02-09 | $161.40M derived: sum of 3 quarters · filed 2023-02-09 | $280.30M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $94.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $74.10M derived: sum of 2 quarters · filed 2023-02-09 | $193.00M derived: sum of 3 quarters · filed 2023-02-09 | $228.50M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | -$20.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $98.50M derived: sum of 2 quarters · filed 2021-11-01 | $134.00M 10-Q · filed 2021-11-01 | $139.60M 10-Q · filed 2020-11-09 | $231.50M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2020-06-30 | $118.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $154.40M 10-Q · filed 2021-08-03 | $157.10M 10-Q · filed 2020-08-03 | $251.90M derived: sum of 3 quarters · filed 2022-02-11 | $349.70M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2020-03-31 | $35.50M 10-Q · filed 2021-05-05 | $38.20M 10-Q · filed 2020-05-06 | $133.00M derived: sum of 2 quarters · filed 2022-02-11 | $230.80M derived: sum of 3 quarters · filed 2022-02-11 | $295.00M derived: sum of 4 quarters · filed 2022-02-11 | |||
| 2019-12-31 | $97.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $195.30M derived: sum of 2 quarters · filed 2022-02-11 | $259.50M derived: sum of 3 quarters · filed 2022-02-11 | $147.00M 10-K · filed 2022-02-11 | $152.05M 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $97.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $162.00M derived: sum of 2 quarters · filed 2020-11-09 | $49.50M 10-Q · filed 2020-11-09 | $49.50M 10-Q · filed 2019-11-04 | $99.99M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-06-30 | $64.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | -$48.30M 10-Q · filed 2020-08-03 | -$48.33M 10-Q · filed 2019-07-29 | $2.19M derived: sum of 3 quarters · filed 2021-02-05 | $71.11M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2019-03-31 | -$112.50M 10-Q · filed 2020-05-06 | -$112.49M 10-Q · filed 2019-04-29 | -$62.01M derived: sum of 2 quarters · filed 2021-02-05 | $6.91M derived: sum of 3 quarters · filed 2021-02-05 | $27.39M derived: sum of 4 quarters · filed 2021-02-05 | |||
| 2018-12-31 | $50.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05 | $119.41M derived: sum of 2 quarters · filed 2021-02-05 | $139.89M derived: sum of 3 quarters · filed 2021-02-05 | $101.40M 10-K · filed 2021-02-05 | $101.36M 10-K · filed 2019-02-08 | |||
| 2018-09-30 | $68.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $89.40M derived: sum of 2 quarters · filed 2019-11-04 | $50.91M 10-Q · filed 2019-11-04 | $91.48M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-06-30 | $20.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | -$18.01M 10-Q · filed 2019-07-29 | $22.57M derived: sum of 3 quarters · filed 2020-02-07 | $13.26M derived: sum of 4 quarters · filed 2020-02-07 | ||||
| 2018-03-31 | -$38.49M 10-Q · filed 2019-04-29 | $2.09M derived: sum of 2 quarters · filed 2020-02-07 | -$7.22M derived: sum of 3 quarters · filed 2020-02-07 | |||||
| 2017-12-31 | $40.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $31.27M derived: sum of 2 quarters · filed 2020-02-07 | -$94.33M 10-K · filed 2020-02-07 | |||||
| 2017-09-30 | -$9.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$134.91M 10-Q · filed 2018-11-05 | ||||||
| 2017-06-30 | -$125.60M 10-Q · filed 2018-07-31 | |||||||
| 2016-12-31 | -$106.18M 10-K · filed 2019-02-08 | |||||||
| 2013-12-31 | -$10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$21.66M derived: sum of 2 quarters · filed 2014-02-11 | -$31.52M derived: sum of 3 quarters · filed 2014-02-11 | -$29.61M 10-K · filed 2014-02-11 | ||||
| 2013-09-30 | -$10.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | -$20.64M derived: sum of 2 quarters · filed 2013-10-29 | -$18.73M 10-Q · filed 2013-10-29 | -$27.64M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2013-06-30 | -$9.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | -$7.95M 10-Q · filed 2013-07-26 | -$16.86M derived: sum of 3 quarters · filed 2014-02-11 | -$25.16M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2013-03-31 | $1.91M 10-Q · filed 2013-05-02 | -$7.00M derived: sum of 2 quarters · filed 2014-02-11 | -$15.30M derived: sum of 3 quarters · filed 2014-02-11 | -$22.18M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-12-31 | -$8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$17.21M derived: sum of 2 quarters · filed 2014-02-11 | -$24.09M derived: sum of 3 quarters · filed 2014-02-11 | -$35.29M 10-K · filed 2014-02-11 | ||||
| 2012-09-30 | -$8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | -$15.18M derived: sum of 2 quarters · filed 2013-10-29 | -$26.39M 10-Q · filed 2013-10-29 | -$15.37M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | -$6.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | -$18.08M 10-Q · filed 2013-07-26 | -$7.06M derived: sum of 3 quarters · filed 2014-02-11 | -$4.29M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$11.20M 10-Q · filed 2013-05-02 | -$184.00K derived: sum of 2 quarters · filed 2014-02-11 | $2.59M derived: sum of 3 quarters · filed 2014-02-11 | -$3.32M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $13.79M derived: sum of 2 quarters · filed 2014-02-11 | $7.88M derived: sum of 3 quarters · filed 2014-02-11 | -$698.00K 10-K · filed 2014-02-11 | -$681.00K 10-K · filed 2012-02-09 | |||
| 2011-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | -$3.14M derived: sum of 2 quarters · filed 2012-10-31 | -$11.72M 10-Q · filed 2012-10-31 | -$16.25M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-06-30 | -$5.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-31 | -$14.49M 10-Q · filed 2012-07-31 | -$19.02M derived: sum of 3 quarters · filed 2013-02-08 | -$17.88M derived: sum of 4 quarters · filed 2013-02-08 | ||||
| 2011-03-31 | -$8.58M 10-Q · filed 2012-05-02 | -$13.11M derived: sum of 2 quarters · filed 2013-02-08 | -$11.97M derived: sum of 3 quarters · filed 2013-02-08 | |||||
| 2010-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | -$3.39M derived: sum of 2 quarters · filed 2013-02-08 | $49.94M 10-K · filed 2013-02-08 | |||||
| 2010-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $54.47M 10-Q · filed 2011-10-31 | ||||||
| 2010-06-30 | $53.33M 10-Q · filed 2011-07-29 | |||||||
| 2009-12-31 | -$53.09M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |